2022: A Look at Key Priorities for Control Bionics

Having achieved a year of strong growth, Control Bionics (ASX:CBL) is forging ahead in the current year to level up its momentum as it aims to emerge as a leading player in the innovative augmentative communications and control (ACC) device space.

The article features a description of the company’s robust first-half performance (including a strong opportunity pipeline and new product launches) and strategic priorities for the year ahead.

Check out the highlights, or read the full article here.

  • Control Bionics aims for global expansion of its role in commercialisation, and sale of AAC solutions for people with disabilities.
  • The Company registered 18% revenue growth in the first half.
  • CBL is targeting higher revenue growth across the board by widening its network of partners and sales team channels in the current year.
  • Control Bionics is committed to broadening its product range with an eye-gaze only product, upgradable to Trilogy.

You'll Also Like